- Raw materials
- Antimetabolites
- Seladelpar
Seladelpar API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Seladelpar | CAS No: 851528-79-5 | GMP-certified suppliers
A medication that targets hyperlipidemia and metabolic disorders by modulating lipid metabolism and fatty acid oxidation to support lipid regulation and metabolic balance.
Therapeutic categories
Product Snapshot
- Seladelpar is an oral small molecule formulation
- Its main therapeutic uses include treatment of liver-related conditions such as primary biliary cholangitis and nonalcoholic steatohepatitis
- The compound is currently in investigational status without FDA or EMA approval
Clinical Overview
Pharmacologically, Seladelpar functions as a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Activation of PPARδ modulates transcription of genes involved in lipid and glucose metabolism, though detailed pharmacodynamic profiles specific to Seladelpar remain under investigation. The drug’s mechanism of action is associated with the regulation of fatty acid oxidation pathways and modulation of lipid homeostasis, contributing to its hypolipidemic activity observed in clinical trials.
ADME parameters for Seladelpar have not been fully characterized in the public domain. Given its classification among fatty acids and acyclic compounds, absorption and metabolism may involve hepatic pathways common to lipid-modulating agents. Elimination and bioavailability data are not comprehensively reported.
Safety and toxicity profiles are based on limited clinical trial data since Seladelpar remains experimental and has not received regulatory approval. Potential adverse effects and long-term safety outcomes require further elucidation through ongoing studies.
Seladelpar has been investigated under the code name MBX-8025 in clinical trials targeting hyperlipidemia and related metabolic disorders. It is not yet marketed under any approved brand.
For API sourcing and quality control, procurement of Seladelpar should ensure compliance with specifications pertinent to phenoxyacetic acid derivatives, including purity, residual solvents, and stability parameters. Due to its investigational status, manufacturers must verify certificate of analysis, batch-to-batch consistency, and adherence to GMP standards to support clinical and regulatory requirements.
Identification & chemistry
| Generic name | Seladelpar |
|---|---|
| Molecule type | Small molecule |
| CAS | 851528-79-5 |
| UNII | 7C00L34NB9 |
| DrugBank ID | DB12390 |
Formulation & handling
- Seladelpar is a small molecule intended for oral administration due to its low water solubility and oral bioavailability profile.
- High lipophilicity (LogP 5.07) suggests formulation strategies should address solubility enhancement and potential bioavailability challenges.
- No specific peptide or biologic-related stability concerns reported; standard handling precautions for small molecules apply.
Regulatory status
Seladelpar is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
